Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19
Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19
Abstract We estimated risk of death in vaccinated compared to unvaccinated COVID-19 cases. Cases vaccinated with 1 dose of BNT162b2 had 44% reduced risk of death, 55% with 1 dose of ChAdOx1, and 69% with 2 doses of BNT162b2. This is on top of the protection provided against becoming a case.
Bernal Jamie Lopez、Andrews Nick、Ramsay Mary、Stowe Julia、Gower Charlotte、Simmons Ruth、Tessier Elise
Public Health England||NIHR Health Protection Research Unit in Vaccines and Immunisation||NIHR Health Protection Research Unit in Respiratory InfectionsPublic Health England||NIHR Health Protection Research Unit in Vaccines and ImmunisationPublic Health England||NIHR Health Protection Research Unit in Vaccines and ImmunisationPublic Health EnglandPublic Health EnglandPublic Health EnglandPublic Health England
预防医学医药卫生理论医学研究方法
Bernal Jamie Lopez,Andrews Nick,Ramsay Mary,Stowe Julia,Gower Charlotte,Simmons Ruth,Tessier Elise.Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19[EB/OL].(2025-03-28)[2025-09-04].https://www.medrxiv.org/content/10.1101/2021.05.14.21257218.点此复制
评论